ArticleBMC pulmonary medicine2023
Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients.
Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.Frontiers in immunology · 2023Pooled it
- Apparentness of Unseen Rejection Episodes Post Lung rLTx Is Reliably Enabled by ddcfDNA Detection.HLA · 2026Article
- Donor-derived cell-free DNA testing for noninvasive monitoring of allograft rejection after lung transplantation.Frontiers in immunology · 2026Article
- Donor-Derived Cell-Free DNA in Acute and Chronic Rejection of Solid Allograft Transplantation.Results and problems in cell differentiation · 2026Review
- Donor-Derived Cell-Free DNA in Allograft Transplantation: Exaggerated Hope or Cautious Reality?Biomedicines · 2025Review
- %dd-cfDNA: The New Frontier for Heart/Lung Transplant Surveillance?Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Biomarkers for primary graft dysfunction after lung transplantation: a review of current evidence and future prospects.Frontiers in physiology · 2025Review
- Detection of lung allograft injury through a comprehensive multidisciplinary analysis of donor-derived cell-free DNA in plasma and bronchoalveolar lavage: a real-world single center experience.Frontiers in immunology · 2025Article
- Donor-derived cell-free DNA is a valuable monitoring tool after single lung transplantation: Multicenter analysis.JHLT open · 2024Article
- Hypobaric hypoxia modulated structural characteristics of circulating cell-free DNA in high-altitude pulmonary edema.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Donor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study.Frontiers in transplantation · 2024Article
- Donor Fractions of Cell-Free DNA Are Elevated During CLAD But Not During Infectious Complications After Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- A review of cell-free DNA and epigenetics for non-invasive diagnosis in solid organ transplantation.Frontiers in transplantation · 2024Review
- Molecular monitoring of lung allograft health: is it ready for routine clinical use?European respiratory review : an official journal of the European Respiratory Society · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDonor-derived cell-free DNA (dd-cfDNA) has been applied to monitor acute rejection (AR) in kidney and heart transplantation. This study was aimed to investigate the application of dd-cfDNA levels in the diagnosis of AR and chronic lung allograft dysfunction (CLAD) among the lung transplantation recipients (LTRs).
methodsOne hundred and seventy LTRs were enrolled at the First Affiliated Hospital of Guangzhou Medical University between 1 June 2015 and 30 March 2021. Patients were divided into 4 groups: stable group, AR group, infection group and CLAD group. The level of dd-cfDNA was analyzed using target region sequencing and the performance characteristics of dd-cfDNA for diagnosis of AR and CLAD were determined, respectively.
resultsKruskal-Wallis test showed that there were some significant differences in the level of dd-cfDNA (%) among the 4 groups, with p < 0.001. Among them, the level of dd-cfDNA (%) was highest (median 2.17, IQR [1.40-3.82]) in AR group, and higher in CLAD group (median 1.07, IQR [0.98-1.31]), but lower in infection group (median 0.71, IQR [0.57-1.07]) and lowest in stable group (median 0.71, IQR [0.61-0.84]). AUC-ROC curve analysis showed that the threshold of dd-cfDNA for AR was 1.17%, with sensitivity being 89.19% and specificity being 86.47%, and the optimal threshold of 0.89% was determined of CLAD, with sensitivity being 95.00% and specificity of 76.99%.
conclusionsPlasma dd-cfDNA could be a useful tool for the assessment of lung allograft rejection, including AR and CLAD, and holds promise as a noninvasive biomarker for "allograft injury" in both acute and chronic rejection following lung transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.